Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Taiho to Terminate Multinational PIII Study of Angiogenesis Inhibitor Orantinib for Hepatocellular Carcinoma
August 4, 2014
- Daiichi Sankyo to Transfer Akita Plant to Alfresa Pharma
August 4, 2014
- Kyowa Kirin, AstraZeneca Hook Up in Immuno-Oncology Clinical Study
August 1, 2014
- Kyowa Kirin Taking Nesp Issue Seriously from Ethical Standpoint: Pres.
August 1, 2014
- Anticancer Agent Lenvatinib Granted EMA Accelerated Review: Eisai
August 1, 2014
- Kyowa Kirin to Outsource Sales of Recombinant Human Antithrombin Preparation to JB
August 1, 2014
- Takara Bio to Buy Swedish Stem Cell Company
July 31, 2014
- Kyowa Kirin’s Half-Year Pharma Operating Profit Tumbles 41% on Price Cuts
July 31, 2014
- Nissan Chemical Files Livalo Patent Suit against Sawai in US
July 31, 2014
- Sanofi Files NDA for HOE901-U300, Successor Drug to Lantus, in Japan
July 31, 2014
- LSI Medience, Kyushu TLO Jointly Set Up KPSL, New Business Entity in Clinical Laboratory Test Field
July 31, 2014
- Kyowa Kirin Begins PI Study for XLH Adult Patients in Japan, South Korea
July 30, 2014
- Alfresa Group Companies Tokiwa Yakuhin and Seiwa Sangyo to Merge
July 30, 2014
- Meiji Seika Pharma Licenses Opalmon from Ono for Its Commercialization in Thailand and Indonesia
July 29, 2014
- AbbVie Hopes to Make Humira Major Drug for Biologics-Naïve Patients: President
July 28, 2014
- New Guidelines for Investigator-Led Trials to Take Effect at August-End: Novartis Japan
July 28, 2014
- Januvia Ranked No.1 in GP Market in June: Anterio’s “Mind Share” Ranking
July 28, 2014
- TS-1 Fails to Meet Primary Endpoint in PIII Study in Japan for Advanced Hepatocellular Carcinoma: Taiho
July 28, 2014
- Chugai Half-Year Earnings Upbeat on Actemra; Anti-PCSK9 Drug Ditched from Pipeline
July 25, 2014
- Kyowa Kirin Launches PII Study for XLH Drug KRN23 in US, Europe
July 25, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…